Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC
NCT04098458 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2021-03-22
Summary
Head and neck cancer squamous cell carcinoma (HNSCC) is a disease with poor survival, especially for African Americans, despite intense treatment including surgery, radiation, and chemotherapy. Delays between surgery and the start of postoperative radiation therapy (PORT) are common, cause excess mortality, and contribute to worse survival in African Americans. Our research team has developed NDURE (Navigation for Disparities and Untimely Radiation thErapy), a novel theory-based patient navigation (PN) intervention to decrease delays and racial disparities starting PORT. In this single-site, open label, single-arm trial, adults with surgically-managed, locally advanced HNSCC, will be enrolled in NDURE to assess the feasibility and acceptability of NDURE as a novel approach to decreasing delays and racial disparities starting PORT after surgery for HNSCC. The investigators will collect information about the accrual rate and NDURE completion rate. Participants will also complete validated questionnaires at baseline and post-intervention to evaluate the feasibility of outcome assessment for NDURE. Post-intervention, patients and providers will undergo interviews to obtain in-depth understanding of the content, format, timing, and delivery of NDURE to optimize the intervention in preparation for a future multi-site study. NDURE could provide the first effective intervention to improve the delivery of timely, equitable PORT after HNSCC surgery, thereby improving survival for patients with HNSCC, decreasing racial disparities in mortality, and developing new standards of clinical care.
Conditions
- Squamous Cell Carcinoma of Head and Neck
Interventions
- BEHAVIORAL
-
NDURE
NDURE consists of 6 key functions including (1) Improve patient knowledge about guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care. Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each at the pre-surgical consult, hospital discharge, and first postoperative visit.
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Medical University of South Carolina
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-12
- Primary Completion
- 2020-04-14
- Completion
- 2020-04-14
Countries
- United States
Study Locations
More Related Trials
-
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
NCT00485485 ·Status: COMPLETED ·Phase: PHASE2
-
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00054054 ·Status: COMPLETED ·Phase: PHASE2
-
Implementation and Effectiveness Trial of HN-STAR
NCT04208490 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC
NCT00483821 ·Status: COMPLETED
-
Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma
NCT06218004 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
NCT02126969 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
NCT01312350 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer
NCT01111942 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
NCT06102395 ·Status: RECRUITING ·Phase: PHASE3
-
Chemo-embolization for Head and Neck Cancer
NCT04595981 ·Status: WITHDRAWN ·Phase: PHASE2
-
Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT02997332 ·Status: TERMINATED ·Phase: PHASE1
-
Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma (neoHNSCC)
NCT06011993 ·Status: UNKNOWN
-
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
NCT03726775 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma
NCT05845632 ·Status: UNKNOWN
-
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
NCT00509665 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
NCT00148122 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT01064479 ·Status: COMPLETED ·Phase: PHASE2
-
Access to Care Pilot for ED-Presenting Head and Neck Cancer Patients (ENRICH-HNC)
NCT07225725 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma
NCT06957938 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Web-Based Program in Helping Patients With Head and Neck Cancer Adhere to Swallowing Exercises and Coping Strategies
NCT04003051 ·Status: RECRUITING ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
NCT02388932 ·Status: TERMINATED ·Phase: NA
-
Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma
NCT06199271 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT00494182 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC
NCT02047201 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
NCT04572100 ·Status: COMPLETED ·Phase: PHASE1